ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded to "Sell" Rating by StockNews.com

StockNews.com downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) from a hold rating to a sell rating in a report released on Tuesday.

Several other equities research analysts have also commented on ANIP. Truist Financial upped their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research report on Tuesday, October 22nd. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an "outperform" rating and a $80.00 target price on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Finally, HC Wainwright restated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $77.71.

ANI Pharmaceuticals Trading Down 1.5 %

NASDAQ:ANIP traded down $0.92 on Tuesday, reaching $58.64. 119,741 shares of the stock traded hands, compared to its average volume of 159,698. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81. The company's 50 day moving average is $56.61 and its 200-day moving average is $58.57. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -106.62 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.05 earnings per share. Equities research analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now owns 49,059 shares of the company's stock, valued at $2,943,540. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,381 shares of company stock worth $2,441,556. Insiders own 12.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 4.2% in the 4th quarter. Principal Financial Group Inc. now owns 93,777 shares of the specialty pharmaceutical company's stock worth $5,184,000 after buying an additional 3,816 shares during the last quarter. Legato Capital Management LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter worth about $334,000. abrdn plc purchased a new position in ANI Pharmaceuticals in the fourth quarter valued at about $13,155,000. China Universal Asset Management Co. Ltd. grew its position in shares of ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after acquiring an additional 412 shares during the period. Finally, BTC Capital Management Inc. increased its stake in shares of ANI Pharmaceuticals by 12.4% during the 4th quarter. BTC Capital Management Inc. now owns 10,623 shares of the specialty pharmaceutical company's stock worth $587,000 after purchasing an additional 1,172 shares during the last quarter. Institutional investors own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.